drugset
drugset / Trial / NCT04887961

Reprab Study: PLD + Trabectedin Rechallenge

NCT04887961 ↗

Phase 2 Unknown 64 enrolled Fondazione Policlinico Universitario Agostino Gemelli IRCCS
NaSingle-groupOpen-labelTreatment

Summary

RECHALLENGE WITH PEGYLATED LIPOSOMAL DOXORUBICIN ADDED TO TRABECTEDIN IN RECURRENT OVARIAN CANCER: A MULTICENTER, PROSPECTIVE TRIAL

Timeline

Start
2020-10-01
Primary completion
2022-04-01
Completion
2022-04-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Doxorubicin Other / unclassified 30 mg/m2 Intravenous
Subject Trabectedin Small molecule 1.1 mg/m2 Intravenous

Indications

No indication recorded.